Opendata, web and dolomites

STRICT SIGNED

SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRICT project word cloud

Explore the words cloud of the STRICT project. It provides you a very rough idea of what is the project "STRICT" about.

ventricle    patented    3b    exams    least    saving    lives    maturation    arrythmia    physical    mortality    activated    overtreatment    difficult    death    sn    status    normal    lt    pinpoint    left    echocardiogram    stratify    coming    arrhythmias    25    never    regime    competitive    patient    cardioverter    defibrillator    51    device    innovation    eligible    risk    biomarkers    assurance    biomarker    ecg    ventricular    global    expertise    20k    surgery    positioning    lvef    levels    diagnostic    burden    icd    implantable    biomedical    35    diagnosis    cardiologists    unknowingly    victims    health    caused    patients    cardiac    decision    boost    trl8    sme    cardinor    worldwide    market    reducing    associate    ejection    alone    survival    skills    scd    blood    house    company    icds    vitro    secretoneurin    67    advantage    recruit    killer    cardiovascular    ask    acquiring    data    sudden    detect    accurate    shown    cvd    ivd    disease    globally    linked    correlation    quality   

Project "STRICT" data sheet

The following table provides information about the project.

Coordinator
CARDINOR AS 

Organization address
address: GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 119˙805 €
 EC max contribution 119˙805 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-2019-02
 Funding Scheme CSA
 Starting year 2019
 Duration (year-month-day) from 2019-12-15   to  2020-12-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDINOR AS NO (OSLO) coordinator 119˙805.00

Map

 Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

H2020 Armenia (2020)

Provision of innovative support services to Armenian SMEs which potential for growth and innovation development.

Read More  

E3Canarias 2020-2021 (2020)

Enhancing the innovation management capacity of SMEs with the Enterprise Europe Network Canarias 2020-2021

Read More  

INNOSUPPORT (2020)

Innovation Management Support for SMEs

Read More